Health & Medicine

STAT+: What to expect from Gossamer Bio's late-stage lung disease study

32 sec read7 views0 listens

Gossamer Bio is set to report results from a Phase 3 clinical trial for pulmonary arterial hypertension by the end of February, which could provide insights into whether pursuing a Phase 3 study based on positive subgroup data from an otherwise negative Phase 2 trial is viable. This outcome matters as it may influence how biotech companies interpret and act upon mixed or disappointing early-stage trial results, offering content creators a noteworthy case study in adaptive clinical research strategies.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets1 day ago27 sec read

Canada poaches 64 global scholars in bid to bolster domestic talent pipeline

Canada has secured the relocation of 64 international academics, primarily from the U.S., to its universities under a new $1.7 billion initiative aimed at boosting research and innovation in key fields like AI, health, and environmental science. This...

Ali Nemati

Real Estate & Home2 days ago27 sec read

Unstable rental housing creating lifelong disadvantages for children, new study warns

A new study by the Australian Housing and Urban Research Institute reveals that children in rental homes move frequently and are more likely to face poor living conditions, negatively impacting their development. This instability affects physical and...

Ali Nemati

Cybersecurity2 days ago27 sec read

Canadian supercomputers are transforming drug discovery: Can they deliver medicines faster?

Researchers at Simon Fraser University have developed an AI framework called CGFlow, which accelerates the design of drug molecules by ensuring they can be synthesized in a laboratory. This advancement is crucial for reducing the time and cost associ...

Ali Nemati